{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"60.8","upperLimit":"71.5","value":"66.4"},{"groupId":"OG001","lowerLimit":"45.4","upperLimit":"61.6","value":"53.9"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"47.8","upperLimit":"59.2","value":"53.7"},{"groupId":"OG001","lowerLimit":"28.0","upperLimit":"43.7","value":"35.8"}]}],"title":"18 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.2","upperLimit":"49.5","value":"43.9"},{"groupId":"OG001","lowerLimit":"20.5","upperLimit":"35.3","value":"27.7"}]}],"title":"24 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"312"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"OS rate at a landmark (12, 18, and 24 months) was defined as the K-M estimated probability of participants who survived due to any cause at the landmark after randomization.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 2: Cemiplimab + Chemotherapy"},{"description":"Placebo matching cemiplimab plus platinum-based doublet chemotherapy","id":"OG001","title":"Part 2: Placebo + Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Part 2 participants only","reportingStatus":"POSTED","timeFrame":"12 months, 18 months, 24 months","title":"Part 2: Estimated Survival Probability","type":"SECONDARY","unitOfMeasure":"Estimated percentage of participants"}